Published in: Molecular Cancer Therapeutics
Authors: Hiroshi Fukushima, Aki Furusawa, Takuya Kato, Hiroaki Wakiyama, Seiichiro Takao, Shuhei Okuyama, Peter L. Choyke, Hisataka Kobayashi
Interleukin 15 (IL-15) is inducer of differentiation and proliferation of CD8+ T cells and NK cells and thus promising candidate for cancer immunotherapy. This study showed therapeutic efficacy increase in vivo when IL15 was combined with cancer cell-targeted photoimmunotherapy using ML7710 laser system. Intratumoral injection of IL-15 was more effective than intraperitoneal in suppressing tumor growth and inducing intratumoral immune responses, including abscopal effects.